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Female cancers such as breast (BC), endometrial (EC) and
ovarian (OC) cancers show a growing incidence rate all
over the world including Russia. In Novosibirsk city the
incidence of BC, EC and OC is approximately 80, 25 и 12
per 100 000 in female population, respectively. In Novosi-
birsk population EC is most commonly found between the
ages of 55 and 60 years, OC – between 45-60 and 55-60
years, BC – between 45-60 years. The age maximum for
uterus myoma and endometrial hyperplasia was 45-50 and
40-45 years respectively. Thus, the peak incidence occurs
in the post-menopausal age group for women with cancer
and pre-menopausal age group for women with benign
tumors. It is generally accepted that estrogens contribute
greatly to the growth and development of these tumors.
We estimated a frequency of allelic variants of estrogen-
metabolizing enzymes CYP1A1, CYP1A2, CYP19 (aroma-
tase) and II-phase enzyme SULT1A1 (Sulfotransferase)
genes in the female Caucasian population in Novosibirsk
region of Russia and their association with the elevated risk
of female cancers. We have shown that for BC significant
differences in the allele distributions for CYP1A1 M1 poly-
morphism between patients (n = 286) and controls (n =
274) were found (OR = 2.05, p = 0.000004). There is a defi-
ciency of a mutant allele A of CYP1A2*1F in BC patients
(OR = 0.72, p = 0.0023) as well as genotypes A/A homozy-
gote’s (OR = 0.048, p = 0.0042) which exhibited a reduc-
tion of BC risk. Women with mutant allele A (OR = 2,03,
p = 0.0003) and genotypes SULT1A1 AG heterozygote’s
(OR = 2,22, p = 0.000005) and homozygote’s A/A (OR =
4,25, p = 0.000004) of SULT1A1 gene exhibited an increase
of BC risk. We examined how genotype was related to the
risk of developing an ER-positive (ER+) and PR-positive
(PR+) BC tumor. We have shown the risk of an ER+ breast
tumor seemed smaller for individuals with the CYP1A1,
CYP19 and SULT1A1 variant allele and genotypes. The
remarkable differences in the allele and genotype distribu-
tions for CYP1A2*1F polymorphism in patients with OC
(n = 125) were found (OR = 0.26, p = 0.0000005). The fre-
quency of a mutant CYP19 heterozygote genotype C/T was
higher in patients with OC and EC (n = 168) compared to
healthy women (OR = 3.87, p = 0.001 and OR = 3.73, p =
0.0004, respectively). The detection of estrogen-metaboliz-
ing enzymes in tumor is also important tool for the treat-
ment and prognosis of cancer. We determined the
expression of ERa, ERb, CYP19, SULT1E1 and STS genes
in studied tumors and revealed several tumor phenotypes.
We have shown the ER+, CYP19+ phenotype in both BC
and EC (60 and 80% cases respectively), whereas ER-,
CYP19- (20% cases) phenotypes was found in BC only. We
also have shown ER-, CYP19+ phenotype in 20% cases of
BC and EC that could be important for the personalized
treatment with aromatase inhibitors. The expression of
STS was increased in 80% of EC tumors. Thus, studied
genes could be appropriate candidates for our understand-
ing their contribution to endocrine disorders and environ-
mentally determined diseases susceptibility. Various
patterns of ER a, b, CYP19, STS gene expression are pro-
mising tool for the personal treatment of female cancers in
additional to HER2/neu and other target genes.
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